Hysbysiad dyfarnu contract
Canlyniadau'r weithdrefn gaffael
Adran I:
Endid
contractio
I.1) Enw a chyfeiriad
UK Biobank Ltd
1-2 Spectrum Way, Adswood
Stockport
SK3 0SA
UK
Ffôn: +44 1614755386
E-bost: andrea.howard@ukbiobank.ac.uk
NUTS: UKD3
Cyfeiriad(au) rhyngrwyd
Prif gyfeiriad: http://www.ukbiobank.ac.uk
Cyfeiriad proffil y prynwr: https://www.mytenders.co.uk/search/Search_AuthProfile.aspx?ID=AA25607
I.4) Y math o awdurdod contractio
Corff a lywodraethir gan gyfraith gyhoeddus
I.5) Prif weithgaredd
Iechyd
Adran II: Gwrthrych
II.1) Cwmpas y caffaeliad
II.1.1) Teitl
Procurement of an Assay to Measure Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Human Blood Samples for the UK Biobank study of seroprevalence of Covid-19
Cyfeirnod: UKBB011
II.1.2) Prif god CPV
85148000
II.1.3) Y math o gontract
Gwasanaethau
II.1.4) Disgrifiad byr
UK Biobank is conducting a study of seroprevalence of Covid-19 in the population of up to 20 000 of its participants and their adult children and grandchildren (the ‘Study’). The study (which is funded by the Department of Health and Social Care) aims to collect blood samples from study participants each month for an initial period of 6 months and measure these samples to assess the extent of previous infection with the SARS‐CoV‐2 coronavirus (by measuring blood antibodies) in different locations and age groups across the UK. In order to enable the study, UK Biobank needed a supplier to provide an assay which could be used to measure blood antibodies. There was an urgent need to identify a supplier of an assay to enable UK Biobank to design the study – in particular the method of blood collection – to enable the study to start without delay. The study needed to start as soon as possible to enable UK Biobank to report the assay results to DHSC to assist the DHSC in its monitoring of Covid-19 in the population as part of its urgent public health response to the Covid-19 pandemic. Whilst it is UK Biobank that has entered into the contract directly with the assay supplier, the DHSC will be remunerating the supplier direct (rather than payment being made through UK Biobank)
II.1.6) Gwybodaeth am lotiau
Mae’r contract hwn wedi’i rannu’n lotiau:
Na
II.1.7) Cyfanswm gwerth y caffaeliad
Gwerth heb gynnwys TAW: 1 560 000.00 GBP
II.2) Disgrifiad
II.2.2) Cod(au) CPV ychwanegol
85140000
II.2.3) Man cyflawni
Cod NUTS:
UKD35
II.2.4) Disgrifiad o’r caffaeliad
Procurement of an assay to measure severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in human blood samples.
II.2.5) Meini prawf dyfarnu
Price
II.2.11) Gwybodaeth am opsiynau
Opsiynau:
Na
II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd
Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd:
Na
Section IV: Gweithdrefn
IV.1) Disgrifiad
IV.1.1) Y math o weithdrefn
Dyfarnu contract heb gyhoeddi galwad am gystadleuaeth yng Nghyfnodolyn Swyddogol yr Undeb Ewropeaidd ymlaen llaw
Cyfiawnhau'r weithdrefn ddyfarnu a ddewiswyd:
Brys eithafol yn sgil digwyddiadau nad oedd modd i’r awdurdod contractio eu rhagweld ac yn unol â’r amodau llym a nodir yn y gyfarwyddeb
Esboniad
UK Biobank (‘UKB’) has relied on Regulation 32(2)(c) of the Public Contracts Regulations 2015 (‘PCR 2015’) to make a direct award due to extreme urgency. In relying on this ground UKB has considered the guidance set out in the Cabinet Office information note ‘Procurement Policy Note – Responding to Covid-19 Information Note PPN 01/20 (March 020)’. The Covid-19 pandemic is so novel that the consequences were unforeseeable. Confirmation as to the need to undertake the Study as a matter of urgency was only confirmed to UKB on 23 April 2020 (with the study starting and blood collection kits being mailed out on 20 May 2020). This urgency did not provide UKB with sufficient time to comply with the usual/accelerated timescales in the PCR 2015 as it was imperative to ascertain which assay was being used in order to design the blood collection methods for the study and get the study started. The urgency UKB is responding to could not have been foreseen and is not due to UKB’s delay in acting. Reliance on Regulation 32(2)(2)(c) was imperative to enable UKB to design and start the study (in the interests of public health as part of the Government’s testing programme ‘Coronavirus (Covid-19) scaling up our testing programmes’ It was not practical to consider entering into a very short term services contract with the appointed contractor whilst a competitive accelerated process was run for the remainder of the study – the same assay needs to be used on all the samples in the study to ensure consistency and reliability of the data being generated and analysed for the purposes of the study.
IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)
The procurement is covered by the Government Procurement Agreement:
Ydy
Section V: Dyfarnu contract
Dyfernir contract/lot:
Ydy
V.2 Dyfarnu contract
V.2.1) Y dyddiad y daeth y contract i ben
05/06/2020
V.2.2) Gwybodaeth am dendrau
Nifer y tendrau a ddaeth i law: 1
Nifer y tendrau a ddaeth i law gan BBaChau: 0
Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau yr UE: 0
Nifer y tendrau a dderbyniwyd gan dendrwyr o Aelod-wladwriaethau nad ydynt yn aelodau o'r UE: 0
Nifer y tendrau a ddaeth i law drwy ddulliau electronig: 1
Dyfarnwyd y contract i gr?p o weithredwyr economaidd:
Na
V.2.3) Enw a chyfeiriad y contractwr
The Chancellor Masters and Scholars of The University of Oxford
University Offices, Wellington Square
Oxford
OX1 2JD
UK
NUTS: UKJ14
BBaCh yw’r contractwr:
Na
V.2.4) Gwybodaeth am werth y contract/lot (heb gynnwys VAT)
Cyfanswm gwerth y contract/lot: 1 560 000.00 GBP
V.2.5) Gwybodaeth am is-gontractio
Section VI: Gwybodaeth ategol
VI.3) Gwybodaeth ychwanegol
(MT Ref:219946)
VI.4) Gweithdrefnau adolygu
VI.5) Dyddiad anfon yr hysbysiad hwn
22/06/2020